Io Biotech, Inc. (IOBTQ) intrinsic value & 10-year financials
Io Biotech, Inc. (IOBTQ) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $6.6K
- Revenue (FY2024)
- —
- ROIC (10-yr avg)
- 1545.8%
- Free cash flow (FY2024)
- -$82.4M
IOBTQ 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | — | -$95.5M | -$1.45 | -$82.4M | — | 951.3% |
| FY2023 | — | -$86.1M | -$1.98 | -$72.1M | — | 1894.6% |
| FY2022 | — | -$71.5M | -$2.48 | -$60.4M | — | 4888.7% |
| FY2021 | — | -$67.9M | -$17.30 | -$40.8M | — | -46.7% |
| FY2020 | — | -$12.0M | — | — | — | 40.9% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
IO Biotech, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
IO Biotech, Inc. returns on capital have been average, hovering around 14.3% ROIC over the decade.
IO Biotech, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
IO Biotech, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.